http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
탐색용 드론의 과학수사학적인 최적 운용방안과 항공 안전법에 관한 검토
신승문,임강수,김용욱,탁희석,류영기 한국과학수사학회 2021 과학수사학회지 Vol.15 No.1
For effective scientific investigative operation of search drones, 1) Establishing support conditions for professionals, equipments, facilities etc of drone operation, at front-line investigation sites. 2) Including drones on the list of essential portable devices for a more rapid drone deployment, 3) Including licensed operators on the mandatory requirement of selection of investigators for specialization of operating workforce, 4) Operating drones proactively to secure the safety of investigators. 5) Tracing the epicenter of illegal drone operations and preventing them from accessing restricted areas. 6) Amending the legal deposition clause of the criminal procedure law to allow utilizing relevant drone footages as evidence against malicious or illegal drone operations. 7) Constitutionalizing relevant laws, operation regulations and cautions to rapidly deploy drones without decision making procedures in case of accidents. If these items are considered and established so that drones can be more efficiently used at various accident sites, precious lives and properties of the Korean people will be more effectively protected.
신승용,박수정,김영,임종필,김효종,이강문,김지원,정성애,이준,강상범,신성재,김은선,김유선,김태오,김현수,박동일,김형길,김은수,김영호,김도현,Dennis Teng,김종화,김원용,최창환 대한장연구학회 2022 Intestinal Research Vol.20 No.3
Background/Aims: This study assessed the efficacy and safety of adalimumab (ADA) and explored predictors of response in Korean patients with ulcerative colitis (UC).Methods: A prospective, observational, multicenter study was conducted over 56 weeks in adult patients with moderately to severely active UC who received ADA. Clinical response, remission, and mucosal healing were assessed using the Mayo score.Results: A total of 146 patients were enrolled from 17 academic hospitals. Clinical response rates were 52.1% and 37.7% and clinical remission rates were 24.0% and 22.0% at weeks 8 and 56, respectively. Mucosal healing rates were 39.0% and 30.1% at weeks 8 and 56, respectively. Prior use of anti-tumor necrosis factor-α (anti-TNF-α) did not affect clinical and endoscopic responses. The ADA drug level was significantly higher in patients with better outcomes at week 8 (<i>P</i><0.05). In patients with lower endoscopic activity, higher body mass index, and higher serum albumin levels at baseline, the clinical response rate was higher at week 8. In patients with lower Mayo scores and C-reactive protein levels, clinical responses, and mucosal healing at week 8, the clinical response rate was higher at week 56. Serious adverse drug reactions were identified in 2.8% of patients.Conclusions: ADA is effective and safe for induction and maintenance in Korean patients with UC, regardless of prior anti-TNF-α therapy. The ADA drug level is associated with the efficacy of induction therapy. Patients with better short-term outcomes were predictive of those with an improved long-term response.